Wave Life Sciences Ltd.
A clinical-stage biotech building a family of RNA medicines through its PRISM platform, which uses chemical tweaks called stereopure chemistry to make drugs that can edit, silence, or splice genetic messages. Its experimental treatments target conditions including obesity, alpha-1 antitrypsin deficiency, and Huntington's disease. Founded in 2012 and first named Ontorii, the company's "Wave" name nods to the wave of RNA innovation, and it manufactures its own medicines at a plant in Lexington, Massachusetts.
Granted 28.8K · Bought 19.25M
Bought 7.56M
Bought 1.88M
Granted 28.8K · Sold 4.9K
Bought 686.6K
Bought 76.3K · Sold 454.6K
Bought 125.0K
Granted 445.4K · Sold 63.7K
Granted 1.22M · Sold 1.14M
Granted 295.2K · Sold 157.0K
Granted 484.6K · Sold 359.1K
Granted 180.9K · Sold 71.8K
Granted 937.3K · Sold 875.4K
Granted 70.8K · Sold 58.1K
Granted 58.9K · Sold 14.0K
Granted 39.0K
Granted 60.3K · Sold 31.1K
Granted 44.9K · Sold 16.1K
Granted 181.7K · Sold 156.3K
Granted 34.0K
Granted 126.3K · Sold 113.6K
Sold 651
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Kolchinsky Peter +3 co-filersDirector, 10% owner · 11 transactions | — | 45.24M | 28.8K | 19.25M | — |
| GSK plc10% owner · 3 transactions | — | 18.25M | — | 7.56M | — |
| Kolchinsky Peter +2 co-filersDirector, 10% owner · 2 transactions | — | 11.13Mas of Nov 2015 | — | 1.88M | — |
| Takanashi KenDirector · 4 transactions | — | 9.63M | 28.8K | — | 4.9K |
| Kolchinsky Peter +1 co-filerDirector, 10% owner · 3 transactions | — | 7.78Mas of Jan 2019 | — | 686.6K | — |
| Kagoshima Shinsangyo Sousei Investment Limited Partnership +1 co-filer10% owner, Director, 10% owner · 5 transactions | — | 5.57Mas of Sep 2017 | — | 76.3K | 454.6K |
| Takanashi Ken +1 co-filer10% owner, Director, 10% owner · 2 transactions | — | 3.56Mas of Nov 2015 | — | 125.0K | — |
| Vargeese ChandraSee Remarks · 27 transactions | — | 408.2K | 445.4K | — | 63.7K |
| Bolno PaulPresident and CEO, Director · 47 transactions | — | 275.5K | 1.22M | — | 1.14M |
| Verdine Gregory L.Director · 15 transactions | — | 275.2K | 295.2K | — | 157.0K |
| Moran KyleChief Financial Officer · 25 transactions | — | 134.4K | 484.6K | — | 359.1K |
| Panzara Michael A.See Remarks · 18 transactions | — | 109.1Kas of May 2022 | 180.9K | — | 71.8K |
| Francis ChrisSee Remarks · 65 transactions | — | 61.9K | 937.3K | — | 875.4K |
| Rawcliffe AdrianDirector · 5 transactions | — | 54.7K | 70.8K | — | 58.1K |
| Wagner Heidi LDirector · 6 transactions | — | 44.9K | 58.9K | — | 14.0K |
| Baldry MarkChief Commerical Officer · 2 transactions | — | 39.0Kas of Aug 2019 | 39.0K | — | — |
| Regnante KeithChief Financial Officer · 7 transactions | — | 29.2Kas of Mar 2019 | 60.3K | — | 31.1K |
| Corrigan MarkDirector · 4 transactions | — | 28.8K | 44.9K | — | 16.1K |
| Tan Aik NaDirector · 17 transactions | — | 25.4K | 181.7K | — | 156.3K |
| Guerciolini RobertoSee Remarks · 4 transactions | — | 20.0Kas of Dec 2016 | 34.0K | — | — |
| Henry Christian ODirector · 12 transactions | — | 12.7K | 126.3K | — | 113.6K |
| Gaiero David GInterim CFO · 1 transaction | — | 6.4Kas of Feb 2020 | — | — | 651 |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +26.06M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.